A biopharmaceutical manufacturer approached Avalere Health for support in assessing emerging global trends in value, health technology assessment (HTA), and payer policies across 11 priority markets and select multilateral institutions. The client commissioned us to deliver an actionable dashboard that synthesized trends and developments relevant to its portfolio and therapeutic area priorities, with recommendations for policy engagement and advocacy.
The client established a new, above-brand, cross-functional steering committee that would shape the company’s global policy and advocacy strategy. The committee needed a mechanism to track and analyze extensive information on trends in value, HTA, and payer policies across major markets in priority therapeutic areas such as oncology, specialty drugs, and vaccines. The committee also sought information on opportunities to engage with key multilateral organizations and global value influencers. In addition to monitoring these developments, the client aimed to translate this information into comprehensive, multi-level strategies in prioritized therapeutic areas across markets.
We created a three-stage quarterly workflow to provide in-depth business intelligence on the client’s markets and therapeutic areas of interest.
The client’s global steering committee has used our quarterly analyses and recommendations to develop in-depth business intelligence on emerging trends in value, HTA, and payer policies in priority international markets and therapeutic areas, helping the organization to establish a strong, above-brand policy and access strategy worldwide. These quarterly reports serve as pre-read decks for steering committee meetings and the recommendations contained in the reports guide steering committee agendas.
Get in touch to leverage our connected policy, access, value, and evidence solutions
Working across the product and service life cycle, from pre-clinical to post-launch, we partner with our clients to navigate the complex and rapidly changing healthcare ecosystem. Get in touch for a confidential conversation about how we can support you with your policy, access, value, and evidence strategies.